Santhera promotes Shabir Hasham to post of CMO

Swiss rare diseases specialist Santhera Pharmaceuticals (SIX: SANN) has appointed Shabir Hasham as chief medical officer (CMO) and a member of its executive management team, effective May 1.

Dr Hasham has served as Santhera’s global development program lead and global head medical affairs for the past three years. In this role, he was primarily responsible for overseeing the clinical development and regulatory submission of vamorolone for the treatment of Duchenne muscular dystrophy (DMD), which culminated in the start of the rolling NDA submission to the US Food and Drug Administration in March 2022, and for supporting launch preparations for this lead product candidate. He previously served as Santhera’s head of medical affairs EU & RoW.

Before joining Santhera in 2015, Dr Hasham held various positions at Novartis (NOVN: VX) including EU medical director and global associate brand director for the Neuroscience franchise at Novartis Pharma, and senior medical manager at Novartis Oncology, contributing to global and regional clinical development, medical affairs and launch plans for new products.